Abstract
In this projection exercise, we analyzed the circumstances of the COVID-19 pandemic in Bangladesh and used multiple methods to characterize the epidemic curve. We merged several publicly available data sets for the purpose. Projections using actual Government data as of June 16, 2020 reveals that the epidemic curve for Bangladesh may be different from that of developed countries and quite similar to such curves in countries in the region. This is true, both in terms of incidence of cases (total number of cases per million population) and length of the epidemic (months to peak or flatten the epidemic curve). We find that while Bangladesh went into lockdown early, efforts to maintain lockdown at a national level was relaxed and new cases accelerated; with significant growth happening since lifting of lockdown on May 31. Our estimates indicate prevalence of COVID-19 may be between 200,000 and 600,000 towards end of the year, may take 9 months (270 days) to flatten the epidemic curve, lifting of the lockdown may have increased total cases by 60 to 100% and may have prolonged the epidemic by additional 2-3 months.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Authors did not recieve any external funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval has been recieved by the director.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Title changed to better reflect content of the article. References reformatted to improve legibity. Line numbers added for better review proess. Some paragraph(lines 135 to 137) re-writtent to clarify.
Data Availability
Data will be available upon request.
